IN THE CLAIMS

Please amend the claims as follows:

Please amend the claims as follows:

1. (Currently Amended) A method of treating ~~a neurological condition~~ traumatic brain injury in a mammal, comprising administering to the mammal ~~a hematopoietic factor selected from the group consisting of GMCSF, a GMCSF derivative, GCSF, a GCSF derivative, and~~ G-CSF, a protein having at least 90% homology to SEQ ID NO:28 and G-CSF activity, a G-CSF peptidomimetic, G-CSF comprising one or more chemical substituents, G-CSF fused to a second protein, a protein fragment of G-CSF having G-CSF activity, or a modified polypeptide of G-CSF having G-CSF activity, or combinations thereof in an amount sufficient to treat the traumatic brain injury ~~neurological condition~~.
2. (Cancelled).
3. (Cancelled).
4. (Cancelled).
5. (Original) The method of Claim 1, further comprising administering one or more additional hematopoietic factors.
6. (Original) The method of Claim 5, wherein the additional hematopoietic factors are selected from the group consisting of a macrophage stimulating factor, an interleukin, and erythropoietin.
7. (Original) The method of Claim 6, wherein G-CSF and erythropoietin are administered to the mammal.
8. (Cancelled).
9. (Currently Amended) The method of Claim 1, wherein ~~the hematopoietic factor is~~ human G-CSF is administered ~~GCSF~~ ~~or a GCSF derivative~~.

10. (Cancelled).

11. (Original) The method of Claim 1, which further comprises administering a hemodynamically active compound.

12. (Original) The method of Claim 1, which further comprises administering tissue plasminogen activator to the mammal.

13. (Original) The method of Claim 1, which further comprises administering an agent that facilitates passage over the blood brain barrier.

14. (Original) The method of Claim 1, which further comprises administering an anti-apoptotic agent.

15. (Cancelled).

16. (Original) The method of Claim 7, further comprising administering tissue plasminogen activator to the mammal.

17. (Original) The method of Claim 1, wherein the hematopoietic factor is a human factor or derived from a human factor.

18. (Original) The method of Claim 1, wherein the mammal is human.

19. (Original) The method of Claim 1, wherein the hematopoietic factor is administered by one or more modes of administration selected from the group consisting of direct intracerebral injection, intravenously, intraarterially, orally, and subcuteneously.

Claims 20-104 (Cancelled).

105. (Currently Amended) A method of treating ~~a neurological condition~~ traumatic brain injury in a mammal, comprising administering to the mammal ~~a hematopoietic factor selected from the group consisting of GMCSF, a GMCSF derivative, GCSF, a GCSF derivative, and~~ G-CSF, a protein having at least 90% homology to SEQ ID NO:28 and G-CSF activity, a G-CSF

peptidomimetic, G-CSF comprising one or more chemical substituents, G-CSF fused to a second protein, a protein fragment of G-CSF having G-CSF activity, or a modified polypeptide of G-CSF having G-CSF activity, or combinations thereof in an amount sufficient to treat the ~~neurological condition~~ traumatic brain injury via stimulation of adult neuronal stem cells.